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Stem Cells from Blood to Heart
In this issue, two independent groups demonstrate that human cord blood (CB) is a ready source of somatic cells that can be reprog-
rammed to pluripotency. In their Brief Report, Belmonte and colleagues reprogram CD133+ CB cells with as few as two transcription
factors, Oct4 and Sox2, to generate teratoma-forming human iPSCs. Interestingly, this population repro-
grams with a higher efficiency—and with fewer factors—than fibroblasts. Using a distinct but related
approach, Martin and coauthors also generate hiPSCs from CB, this time using CD34-expressing cells.
Importantly, the authors also succeed in generating functional cardiomyocytes from their reprogrammed
cells, among other differentiated cell types. In their Review article, Chien and colleagues highlight the chal-
lenges facing the regenerative medicine community in its aim to develop stem cell-mediated therapies, using
cardiovascular disease as a specific example. On the basis of recent advances from both the Belmonte and
Martin laboratories, CBmay become a preferred cell source of donor material for use in future iPSC-mediated
therapies, particularly for newborn and pediatric patients, given that the younger cells may have accumulated
fewer mutations than those isolated from an adult.
Tapping Hematopoiesis from New Angles
HSCs are one of the few readily accessible stem cell populations that can be isolated from adult tissues, and yet even with advances
inmobilization and purification protocols, the numbers retrieved are often limiting. In this issue, Dzierzak and colleagues demonstrate
that full-term human placenta harbors a population of multilineage hematopoietic cells that can repopulate immunodeficient mice
and thus that this commonly discarded tissue may represent an untapped source of HSCs for research or therapeutic purposes.
Even with a new source of HSCs available, ongoing animal studies are required to provide important insights into themolecular regu-
lation of the pathways that control HSC proliferation and differentiation. Also in this issue, Orkin and coauthors report that the DNA
methyltransferase Dnmt1 influencesmurine HSC self-renewal and differentiation, and loss of the same gene leads to the disruption of
methylation patterns on a distinct set of genes in HSCs versus more differentiated progenitors. Uncovering the connection between
specific methylation targets and functional behavior of stem and progenitor cells may help identify candidate pathways to target for
the expansion of therapeutic populations, from a variety of sources.
Regeneration by Replacement
Before human ESCs can begin to fulfill their potential as regenerative building blocks, their developmental
potential must be captured and directed in a routine, reliable manner. Reubinoff and coauthors are making
strides on this front and have now developed hESC culture conditions that generate retinal pigment epithe-
lium (RPE) that is functional after transplantation into an animal model of retinal degeneration. In an earlier
issue of CSC, Lamba et al. (4: 73) also looked at hESC-derived cell integration in the eye and generated
light-sensitive photoreceptors in a mouse model of blindness. Also in this issue, Arenas and colleagues
use a class of nuclear receptors to augment the production of hESC-derived dopaminergic (DA) neurons,
which are the class of neurons lost in Parkinson’s disease. Deletion of these liver X receptors negatively
impacted neurogenesis in mouse models, whereas stimulation of both mouse and human ESCs with oxy-
sterol ligands led to specific generation of DA neurons, at the expense of less differentiated, proliferating
progenitors. All three studies highlight recent advances in harnessing the power of hESCs for potential clinical
interventions.
From Bench to Bedside—to the Bank?
As research initiatives bring stem cell-mediated therapies closer to the clinic, it is natural—and many would argue necessary—for
those endeavors to be commercialized. The ISSCR recognizes the importance of industrial input and has championed a series of
events and initiatives to encourage the involvement of the commercial sector. The 7th annual ISSCR meeting in Barcelona included
a well-attended panel discussion with experts from major biotech and pharmaceutical venues. In the ISSCR section of this issue,
Chris Mason offers a Meeting Report that highlights the details of the event and provides the panel’s list of seven resulting recom-
mendations designed to help guide further responsible commercialization of new therapeutic candidates. Stem cell products that are
moving toward the market include a growing number of pluripotent cell-derived populations, which raises red flags in terms of both
ethical and safety considerations. Douglas Sipp argues, in his Forum article, that the rapid progress of the human iPSC field means
that human pluripotent cells, previously a relatively limited resource for ethical and practical reasons, are now becoming a readily
available commodity that can be derived and used in almost any research lab that is so inclined. How this shift in access and
perceived value might impact actual commercialization and industrial application of pluripotent cell technology remains to be
seen, but Sipp discusses his take on some initial trends and offers some speculation on where the field may be headed.
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